Fibrinolytic system md pathology exam question give Robbins based answer
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
fibrinolysis AND hemostasis
Searching the Web
fibrinolytic system plasminogen plasmin tPA PAI-1 Robbins pathology
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Quick answer
Fibrinolytic system
The fibrinolytic system is a physiological counter-regulatory mechanism that limits thrombus size and ultimately dissolves the fibrin clot after vascular repair. It is activated along with coagulation, thereby ensuring that hemostasis remains localized to the site of injury.
Components and mechanism
1. Plasminogen
- An inactive circulating precursor protein, or zymogen.
- It becomes incorporated into the forming fibrin clot.
- Binding to fibrin causes a conformational change that makes plasminogen more readily activated.
2. Plasminogen activators
- Tissue plasminogen activator (t-PA) is the principal physiological activator.
- Synthesized mainly by endothelial cells.
- Has greatest activity when bound to fibrin, so fibrinolysis is directed mainly to the clot rather than occurring systemically.
- Urokinase (u-PA) can also activate plasminogen.
[
\text{Plasminogen} \xrightarrow[\text{urokinase}]{\text{t-PA}} \text{Plasmin}
]
3. Plasmin
- The active serine protease of the fibrinolytic system.
- Degrades cross-linked fibrin and also interferes with fibrin polymerization.
- This produces soluble fibrin degradation products (FDPs).
4. D-dimer
- A fibrin-derived degradation product produced when cross-linked fibrin is lysed.
- Raised D-dimer supports the occurrence of recent fibrin formation and breakdown, hence it is useful clinically in thrombotic states such as venous thromboembolism and DIC.
- It is not specific for thrombosis and may also rise with inflammation, surgery, malignancy, pregnancy, or age.
Regulation of fibrinolysis
Fibrinolysis must be controlled to prevent inappropriate clot dissolution and bleeding.
| Inhibitor | Action |
|---|---|
| α2-antiplasmin | Binds and rapidly inactivates free circulating plasmin |
| Plasminogen activator inhibitors (PAIs), especially PAI-1 | Inhibit t-PA and urokinase, reducing conversion of plasminogen to plasmin |
| Thrombin-activatable fibrinolysis inhibitor (TAFI) | Reduces plasminogen and t-PA binding to partially degraded fibrin, thereby attenuating fibrinolysis |
Plasmin that is free in the circulation is rapidly neutralized by α2-antiplasmin. Thus, plasmin activity is largely confined to the fibrin clot.
Role of endothelium
Normal endothelium favors fibrinolysis by producing t-PA. In contrast, activated or injured endothelial cells can increase secretion of PAI, shifting the balance toward thrombosis.
Clinical relevance
- Reduced fibrinolysis, including raised PAI-1, favors persistent thrombi and thrombosis.
- Excessive fibrinolysis promotes bleeding.
- Recombinant t-PA may be used therapeutically for thrombolysis because its fibrin-binding property concentrates its action at sites of recent thrombosis.
- In DIC, coagulation and fibrinolytic mechanisms can both be activated, explaining why thrombosis and bleeding may coexist.
Flowchart for writing in exams
Endothelial t-PA / urokinase
↓
Plasminogen bound to fibrin
↓
Plasmin
↓
Cross-linked fibrin degradation
↓
FDPs including D-dimer
PAI-1 inhibits t-PA and urokinase
α2-antiplasmin inhibits free plasmin
TAFI suppresses fibrinolysis
Key sentence: The fibrinolytic system consists of plasminogen activation to plasmin, mainly by endothelial t-PA; plasmin digests fibrin into FDPs including D-dimer, while PAI-1 and α2-antiplasmin restrict this activity and prevent excessive bleeding.
Source: Robbins & Kumar Basic Pathology, Hemostasis section, pp. 86-87.
This is a shared conversation. Sign in to Orris to start your own chat.